Advent Life Sciences
Advent Life Sciences is a venture capital firm dedicated to investing in early-stage and growth equity life sciences companies across the UK, Europe, and the US. They focus on innovative sectors such as new drug discovery, med-tech, enabling technologies, and diagnostics. The firm supports its portfolio with a hands-on approach, working closely with management to bring innovative medicines and products to approval, with a history of successful investments and exits since 2006.
Industries
Nr. of Employees
small (1-50)
Advent Life Sciences
Services
Equity investment (seed to mid-stage)
Direct provision of early and mid-stage capital to life sciences companies, typically from seed or Series A onward.
Operational and strategic advisory
Hands-on support to refine scientific, clinical and business plans, recruit leadership and implement operating plans.
Fundraising and syndication support
Structuring financing rounds, coordinating co-investors and managing milestone-based financing plans.
Regulatory and commercialization advisory
Strategic advice on regulatory pathways and commercialization planning to support market entry and approvals.
Equity investment (seed to mid-stage)
Direct provision of early and mid-stage capital to life sciences companies, typically from seed or Series A onward.
Operational and strategic advisory
Hands-on support to refine scientific, clinical and business plans, recruit leadership and implement operating plans.
Fundraising and syndication support
Structuring financing rounds, coordinating co-investors and managing milestone-based financing plans.
Regulatory and commercialization advisory
Strategic advice on regulatory pathways and commercialization planning to support market entry and approvals.
Expertise Areas
- Venture funding and syndication for life sciences
- Clinical development strategy and protocol planning
- Drug discovery across multiple modalities
- Medtech and device commercialization
- Regulatory strategy and market access planning
- Operational scaling and management team development
- Portfolio exit planning and execution
Key Technologies
- Antibody discovery and display technologies including high-throughput screening and flow cytometry
- High-content cell-based screening
- Cardiac electrophysiology mapping technologies (contact and non-contact, 3D mapping and imaging)
- Catheter-based mapping systems for electrophysiology procedures
- Ultrasound-based intracardiac anatomy reconstruction